Skip to content

Syndax Pharmaceuticals SNDX Cost Of Product Sales

Cost Of Product Sales at other companies

Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$28.81M+25.1%
Ardelyx logo
ArdelyxARDX
$2.88M+22.9%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$1.95M+55.6%
Pfizer logo
PfizerPFE
$3.03B+31.1%
LQD
Liquidia CorporationLQDA
$11.08M
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
$2.28B+16.3%

Segments

By segment

See full
Biopharmaceutical Cancer Therapeutics$2.63M+198%

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.77B+95.0%

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept sndx:CostOfProductSales.

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's cost of product sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Syndax Pharmaceuticals's cost of product sales?
Syndax Pharmaceuticals (SNDX) reported cost of product sales of $2.63M in Q1 2026.
How has Syndax Pharmaceuticals's cost of product sales changed year-over-year?
Syndax Pharmaceuticals's cost of product sales increased by 197.5% year-over-year, from $885K to $2.63M.
What does cost of product sales mean?
This metric represents the direct costs associated with the production and manufacturing of pharmaceutical products sold to customers. It typically includes raw materials, labor, and overhead directly attributable to the goods recognized as revenue during the period. For a clinical-stage company, this reflects the initial commercialization costs and the efficiency of the supply chain for approved therapies.